Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

tors presented positive results from Phase 2 clinical trials of Amigal at the American College of Medical Genetics (ACMG) meeting. The data showed that Amigal was generally safe and well-tolerated at all doses evaluated and no drug-related serious adverse events were reported. In addition, Amigal increased the level of the enzyme deficient in Fabry patients in 24 of 26 study subjects, and in a majority of study subjects the treatment resulted in a reduction of kidney GL-3 as measured in urine.

Amicus, along with its partner Shire, has initiated discussions with the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) regarding its plans for Phase 3 clinical evaluation of Amigal. Amicus expects to complete these interactions and provide an update in the second half of 2008, and subject to the outcome of the discussions, the Company plans to initiate the Phase 3 clinical trial in the first half of 2009.

In parallel with the regulatory process, 23 of the original 26 patients continue to be treated with Amigal in the voluntary Phase 2 extension study to monitor long term safety and efficacy. In addition, the Company will evaluate modified doses and dose regimens in these 23 patients. Data from this extension study are expected to be available by Q1 2009, prior to finalization of the Phase 3 protocol.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic being developed for the treatment of Gaucher disease. At the ACMG meeting in March, clinical investigators presented full data from a 4 week Phase 2 study in Gaucher patients who switched from enzyme replacement therapy (ERT) with imiglucerase to the pharmacological chaperone Plicera. Results showed that Plicera was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. In the trial, GCase activity, as measured in white blood cells, was increased in 20 of the 26 pat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Basel, Switzerland (PRWEB) May 22, 2013 ... solutions for industrial biotechnology, drug discovery, and life ... Genedata Selector ™ as its bioinformatics ... its production-relevant organisms. Genedata will provide AB Enzymes, ... manufacturers, with a hosted solution of Genedata Selector ...
(Date:5/22/2013)... York, NY (PRWEB) May 22, 2013 Mold ... Cleaning Products said that there is a way to cut ... it included on its latest post the details of a ... too much money. , Mold could be prevented, My Cleaning ... measures, the company stated that a mold remediation must then ...
(Date:5/22/2013)... Envera announced today that Michael McErlean has ... has an extensive background in cell production and served ... , Mike Matheny, President and Owner of ... join our team”. “Mike’s background is perfectly suited to ... and downstream processing equipment”, added Matheny. “Mike’s hands on ...
(Date:5/22/2013)... , May 22, 2013  Moderna Therapeutics, the pioneering ... modality to enable the in vivo production ... Reynders will join Moderna in early July ... Reynders is a proven leader in the design and ... development, from discovery to translation, clinical operations and commercial ...
Breaking Biology Technology:AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4How to Kill Mold While Saving Thousands of Dollars on Mold Remediation Projects Explained by My Cleaning Products 2Envera Appoints Michael McErlean Fermentation Manager 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3
... ... Management Solution for European Consortium Using Systems Biology to Study Infectious Diseases , ... (PRWEB) June 1, 2010 ... science research, today announced it has been selected to participate in an ERA-Net-funded applied ...
... 1 eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ... the pharmaceutical, biotechnology, and medical device industries, announced the ... Division of CareFusion Corporation (CRS).  CRS is a leading ... devices and also offers cardiac safety and ePRO services. ...
... Italy , May 31, 2010 ... South East Asia Ltd.,scored two strategic wins by reaching ... and sterile,oncology patient doses in Kuala Lumpur ... first and only robot in the world proven to,automatically ...
Cached Biology Technology:Genedata Phylosopher Selected for ERA-NET sncRNA Project 2Genedata Phylosopher Selected for ERA-NET sncRNA Project 3Genedata Phylosopher Selected for ERA-NET sncRNA Project 4ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation 2ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation 3Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand 2Health Robotics South East Asia Wins two key Cancer Therapy Outsourcing Projects in Malaysia and Thailand 3
(Date:5/21/2013)... that the nation,s land and water resources could likely ... to 25 billion gallons of algae-based fuel a year ... needs. , The findings come from an in-depth look ... grow significant amounts of algae in large, specially built ... 7 issue of Environmental Science and Technology , ...
(Date:5/21/2013)... method for delivering molecules into single, targeted cells ... technique could find applications in drug delivery, cell ... a technique used to deliver molecules into ... that are caused by exposing them to electric ... cell transfection. (Cell transfection is the introduction of ...
(Date:5/21/2013)... Widely available in pharmacies and health stores, phosphatidylserine ... oysters, and soy. Proven to improve cognition and ... older people experiencing memory impairment. Now a team ... Bochner of Tel Aviv University,s Department of ... same supplement improves the functioning of genes involved ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Single-cell transfection tool enables added control for biological studies 2Common food supplement fights degenerative brain disorders 2
... waters interfere with fish reproduction by disrupting the fishes ... at Austin Marine Science Institute has found. Incidents ... have increased dramatically in coastal waters throughout the world ... of increased run-off from human agricultural and industrial activities. ...
... issue of the Journal of the American Dietetic Association contains ... is a summary of one of this months articles. ... Habits Later in Life , Eating together as a family ... quality in young adulthood, according to researchers at the University ...
... The past decade has witnessed an explosion of information ... in the development of obesity and the influence of ... food intake and metabolism. A symposium held recently in ... on recent work in talks by leaders in the ...
Cached Biology News:Low oxygen in coastal waters impairs fish reproduction 2Highlights from the September 2007 Journal of the American Dietetic Association 2Obesity and the central nervous system -- the state of the art 2
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
HyPro 100, includes 5 x HyPro20 and HyPro Cabinet. 100 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Request Info...
Biology Products: